Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1

Figure 6

LRRK2-IN-1 is effective in vivo. AsPC-1 cells (0.5×106) were injected subcutaneously into the flanks of athymic nude mice (n = 4) and allowed to grow until the tumor reached an average volume of 100 mm3. LRRK2-IN-1 was solubilized in 20% Captisol® and xenografts were injected peritumorally with either 20% Captisol (vehicle) or LRRK2-IN-1 (100 mg/kg) for a total of 12 injections. LRRK2-IN-1 treatment resulted in a significant decrease in tumor volume as a function of time (A) and reduced final excised tumor volume (p = 0.09; B-C) and tumor weight (p = 0.14; D). The + symbol denotes the mean.

Back to article page

Molecular Cancer

ISSN: 1476-4598